46 results on '"Fazli L"'
Search Results
2. VAR2-armed CAR T-cells as an immunotherapeutic strategy for bladder cancer
3. DDX5, une nouvelle cible thérapeutique dans le cancer de prostate résistant à la castration
4. A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer progression
5. Head-to-head comparison of efficacy of darolutamide (ODM-201) vs. enzalutamide on mutated forms of the androgen receptor
6. Biological assessment of viable germ cell tumor (VT) in patients (pts) with seminoma (S) and non-seminoma (S) using miR371
7. Tumor regression grading after neoadjuvant chemotherapy in bladder cancer: Validation in an independent cohort
8. Targeting enzalutamide-resistant prostate cancer using the novel androgen receptor inhibitor ODM-201
9. Targeting heat-shock protein 27 enhances sensitivity to sorafenib treatment in renal cancer in vitro and in vivo
10. T-DM1, a novel HER2 antibody-cytotoxic drug conjugate, has anti-metastatic potential and is a promising targeted therapy for bladder cancer with HER2 IHC score 2+/3+
11. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality
12. A novel ginsenoside 20(S)-protopanaxadiol inhibits growth of castration-resistant human prostate cancer
13. Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies
14. 209 A phase 1 clinical trial assessing an intravesical administered second-generation antisense oligonucleotide targeting heat shock protein 27 in bladder cancer
15. 929 Targeting lactate transporters for the treatment of urothelial carcinoma
16. 138 Exploring a novel therapeutic target for neuroendocrine prostate cancer using a xenograft model of trans-differentiation
17. 1046 Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma
18. 791 Notch2-HEY axis promotes tumour growth in bladder cancer through cell cycle progression and de-differentiation
19. Evaluation of a Novel Quantitative Digital Pathology Technique as a Tool for Predicting Prostate Cancer Recurrence
20. DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis
21. Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival
22. 63 Erythropoietin accelerates the regeneration of ureteral function in a murine model of obstructive uropathy
23. 495 Divergent androgen regulation of UPR pathways drives prostate cancer
24. Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer
25. 802 A role for the hedgehog effector Gli1 in mediating stent-induced ureteral aperistalsis and smooth muscle dysfunction
26. 522 Targeting HER2 with trastuzumab-DM1 (T-DM1) is highly effective in preclinical models of HER2-overexpressing bladder cancer
27. 39 Notch2 promotes bladder cancer progression: Pre-clinical rationale for a novel targeted therapy
28. 516 Targeting IGF-BP2 and 5 with the bispecific antisense oligodeoxynucleotide OGX-225 in chemoresistant bladder cancer
29. 403 Patient-derived primary xenografts in the preclinical development of novel targeted therapies for bladder cancer
30. The role of DAB2IP in androgen receptor activation during prostate cancer progression
31. 235 Clusterin knockdown synergizes activity of second generation anti-androgen, MDV3100, through enhancing AR degradation and repression of FKBP52 in castrate resistant prostate cancer model
32. 236 The combination of carbidopa plus bicalutamide suppresses androgen-receptor transactivation, induces apoptosis and delays castration-resistant prostate cancer progression
33. Fibroblast growth factor and ornithine decarboxylase 5′UTRs enable preferential expression in human prostate cancer cells and in prostate tumors of PTEN−/− transgenic mice
34. MP-03.04 The Combination Treatment of Bicalutamide Plus Carbidopa Significantly Enhances the in vivo Antitumor Activity on LNCaP Castration-resistant Prostate Cancer Xenograft Tumors Compared To Single Use of Each Drug
35. An evaluation of clusterin antisense inhibitor OGX-011 in combination with the second-generation antiandrogen MDV3100 in a castrate-resistant prostate cancer model.
36. A phase II study of preoperative figitumumab (F) in patients (pts) with localized prostate cancer (PCa).
37. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E
38. Expression of LHRH receptors in prostate cancer cells prior to therapy, following castration, or following treatment with LHRH agonists
39. Five-year relapse-free survival and predictors of relapse following preoperative docetaxel and mitoxantrone for high-risk localized prostate cancer
40. Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells
41. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers
42. Targeting and killing of prostate cancer cells using lentiviral constructs containing a sequence recognized by translation factor eIF4E and a prostate-specific promoter
43. Significance of insulin-like growth factor binding protein-2 in the prognosis of breast cancer and promotion of accelerated growth and chemo-resistance in MDAMB-231 breast cancer model
44. A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy
45. A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy
46. Integrin-linked kinase, a promising cancer therapeutic target: biochemical and biological properties
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.